Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2007

View Archived Issues

New Integrity Disease Briefing highlights head and neck cancers

Preclinical and phase I data on activity of AT-1001 presented

Satraplatin improves pain and PSA responses in phase III trial

Vardenafil studies presented at European Association of Urology congress

LY-2076962, non-morphinan opioid receptor antagonist, evaluated in phase I study

Celsion files for SPA for ThermoDox

MEDI-545 begins clinical evaluation in psoriasis

Novartis signs agreement for branded interferon beta-1b

New therapeutic agents for thrombotic disorders disclosed in recent patent literature

Ethics approval for second phase IIa neuropathic pain study of ACV-1

EvoGenix achieves milestone in GSK collaboration for protein-based therapeutics

Zanaflu registered as brand name for chitosan gel

Recent patents report novel analgesic agents

CHR-2797 begins phase II for AML in elderly patients

Semafore's PI3K inhibitor studied in phase I for solid tumors

Arrowhead Research forms new nanomedicine subsidiary

New agents for treating neurological disorders disclosed in recent patents

Merck & Co. and Schering-Plough to develop new cholesterol lowering product

PF-184298 presented as clinical candidate by Pfizer

Phase III study of vilazodone in depression completes enrollment

European orphan drug designation for enzastaurin in DLBCL

orBec cleared for phase II study in prevention of GVHD

New selective androgen receptor modulator profiled at Merck

BioLineRx in-licenses new therapeutic candidates

Positive phase IIa results for DIO-902 in type 2 diabetes

Cephalon files for European approval of fentanyl effervescent buccal tablet

Modiodal launched in Japan

AZ-004 reduces agitation in schizophrenic patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...